•  
  •  
 

Corresponding Author

Gadwal, Sara

Document Type

Original Article

Abstract

Background: Diabetic macular edema (DME) is a main reason for vision affection when occurred at any stage of diabetic retinopathy. Anti-vascular endothelial growth factor agents is the gold standard treatment for DME. Adjuvant agents may decrease edema and improve vision. Aim of the work: To assess influence of topical dorzolamide–timolol with intravitreal ranibizumab injection (IVR) on anatomical and functional outcomes in DME. Patients & Methods: This prospective cohort study included thirty patients (30 eyes) having type 2 DM, aged 45-60 years, all eyes have DME. They were divided into 2 groups according to treatment protocol: Group 1: 15 patients (15 eyes) received IVR (3 monthly injection of Lucentis® 0.5 mg/0.05 ml) and adjuvant topical dorzolamide-timolol (Xolamol™ eye drops twice daily). Group 2: 15 patients (15 eyes) received IVR only. Results: Mean BCVA variations were significant in both groups, it varied from 0.93 ± 0.23 logMAR at baseline to 0.73 ± 0.27 (P < 0.001) in group 1 & from 0.93 ± 0.3 logMAR to 0.8 ± 0.33 (P = 0.001) in group 2. Variations in mean CMT were significant in both groups, it varied from 568.67 ± 145.76 at baseline to 384 ± 110.63 (P ˂ 0.001) in group 1 & from 513.4 ± 114.54 at baseline to 387.87 ± 119.52 (P ˂ 0.001) in group 2, at 4th month. Conclusion: This study demonstrated that adjuvant topical dorzolamide -timolol with IVR included additional effects, but not a statistically significant, on IVR in treatment of DME over 4-month- course.

Keywords

Diabetic Macular Edema; Dorzolamide-Timolol; Intravitreal Ranibizumab

Download

Share

COinS